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Abstract
Schizophrenia is a complex highly heritable disorder. Genome-wide association studies (GWAS) have identified multiple loci
that influence the risk of developing schizophrenia, although the causal variants driving these associations and their
impacts on specific genes are largely unknown. We identify a significant correlation between schizophrenia risk and
expression at 89 genes in the dorsolateral prefrontal cortex (P≤ 9.43×10−6), including 20 novel genes. Genes whose
expression correlate with schizophrenia were enriched for those involved in abnormal CNS synaptic transmission (PFDR = 0.02)
and antigen processing and presentation of peptide antigen via MHC class I (PFDR =0.02). Within the CNS synaptic transmission
set, we identify individual significant candidate genes to which we assign direction of expression changes in schizophrenia.
The findings provide strong candidates for experimentally probing the molecular basis of synaptic pathology in
schizophrenia.
Introduction
Schizophrenia [OMIM: 181500] is a severe psychiatric disorder
which typically manifests in late adolescence or early adult-
hood (1). Genetic studies have shown that schizophrenia is
multifactorial but highly heritable. The genetic contribution
is polygenic, involving large numbers of risk alleles spanning
the full spectrum of possible allele frequencies (2–4). Regarding
common variation, the most recent genome-wide association
study (GWAS) reported 174 independent association signals
representing 145 distinct associated loci (2).
In principle, each genetic locus identified by GWAS provides
an opportunity to expose a biological mechanism bridging
statistical association and disease. In practice, the imprecision
inherent in GWASmakes extracting biological information from
these studies challenging. This is based on factors such as
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extensive linkage disequilibrium, loci spanning multiple genes
and regulatory motifs and long-range regulatory mechanisms
acting beyond the boundaries of the associated region.
The common variant associations observed in schizophrenia
appear to be largely driven by variation affecting gene expression
or splicing rather than non-synonymous variation (5,6). As such,
there has been considerable interest in integrating GWAS data
with functional annotations defined in appropriate tissues to
identify candidate loci that are not detected by GWAS alone.
Several methods, collectively described as transcriptome-wide
association studies (TWAS) have been developed to achieve this,
including summary Mendelian randomization (SMR) (7), PrediX-
can (8) and FUSION (9). Here the principle is to derive genomic
predictors of gene expression from samples (not necessarily
cases) for which both genomic and gene expression data are
available, and to use those predictors to impute gene expression
in independent samples (e.g. case–control samples) for which
genome-wide association data, but not gene expression data, are
available.
Several TWAS of schizophrenia have been performed, incor-
porating a variety ofmethodologies and source tissues. Applying
the FUSION approach to the second GWAS of schizophrenia
published by the Psychiatric Genomics Consortium (or PGC2),
Gusev and colleagues (10) identified 44 genes for which there
was significant evidence for association between schizophrenia
and the genetically imputed cis-component of gene mRNA
expression in adult postmortem human brain tissue from the
dorsolateral prefrontal cortex (DLPFC). More recently, two
studies have used GWAS summary statistics from the larger
CLOZUK+PGC2 schizophrenia meta-analysis (2). Huckins and
colleagues (11), using PrediXcan and expression data from 13
brain regions, identified 256 genes for which expression was
associated with schizophrenia. The largest number of associ-
ations was observed in the DLPFC, with 49 significant genes
(outside the MHC), of which 24 were conditionally independent.
Gandal and colleagues (12) employed FUSION, incorporating
expression data frommultiple brain regions across several stud-
ies from the PsychENCODE consortium. Gandal and colleagues
also employed an SMR approach to further substantiate their
findings. They identified 164 genes (outwith theMHC). Including
the MHC, they identify 193 TWAS significant genes, of which 107
were conditionally independent, and 62 were supported by SMR.
There are large numbers of genes whose mRNA expression
in non-brain tissues (e.g. fat, peripheral blood, testis) have also
been correlated with schizophrenia (7,10,13,14). While there is
clear evidence for cross-tissue overlap in the effects of gene
variants on gene expression, unless supported by findings in
brain tissue, caution in interpreting those findings in the context
of schizophrenia is required.
Herewe report a TWAS, and subsequent gene-based analysis,
based on the largest published schizophrenia GWAS dataset
(2) and publicly available expression data from the Common-
Mind Consortium study of DLPFC (15).We restricted our analysis
to a single tissue source as enrichments for common variant
genomic and transcriptome-wide polygenic association signals
are effectively restricted to the brain (2,10); therefore, associ-
ations between schizophrenia and heritable gene expression
derived from this tissue have the highest plausibility of being
biologically relevant to disease pathophysiology. Moreover, as a
major aim of our study was to undertake a competitive test-
based pathway analysis, the use of a single tissue considerably
simplifies this as it minimizes biases towards association with
genes expressed in multiple tissues or samples, genes which are
also likely to be biased with respect to gene-set membership.
Results
Transcriptome-wide association study
Of the 5301 genes modeled in our data with significant cis-
heritable expression in the DLPFC, 89 returned a significant
TWAS association signal (P≤9.43×10−6). Twenty of these genes
are not previously reported as significant associations (Table 1).
TWAS test statistics for all genes are shown in Figure 1 and Sup-
plementary Material, Table S1. Schizophrenia liability was not
significantly biased towards increased or decreased expression,
with increased expression being positively correlated with dis-
ease risk at just over half of genes (N=46, sign test P=0.83). Prox-
imal TWAS significant genes (those within a 500-kb window)
were aggregated, resulting in 62 discrete loci (Supplementary
Material, Table S2). Conditional analyses of each locus identified
68 genes with statistically independent TWAS signals (condi-
tional P≤0.05). The TWAS signal could be attributed to a single
gene at 56 of these loci (Supplementary Material, Tables S2
and S3).
Correlation with results from summary-based
Mendelian randomization
Overall, the effect size estimates from our TWAS analysis were
correlated (R=0.71; CI: 0.70–0.73; P<2.2×10−16, Supplementary
Material, Fig. S1) with those obtained using a different method-
ology (SMR) and an only partially overlapping expression dataset
(12). Of the 20 novel genes we report here, only 12 have data
reported in the SMRanalysis; for that set of genes, the correlation
wasmuch stronger (R=0.91; CI: 0.76–0.98; P=1.18× 10−5),with 11
genes significant in the SMR-multi analysis at a threshold allow-
ing for the number of tests (P<0.004) (Supplementary Material,
Table S4).
Correlation with brain-based gene expression in the
fetal brain
The much smaller fetal brain expression dataset yielded fewer
testable genes, with only 486 genes testable across the CMC and
fetal brain dataset. Across all genes, the effect sizes were cor-
related R=0.67 (CI: 0.61–0.72; P<2.2×10−16). Of the nine TWAS-
significant genes from the CMC data that are testable in fetal
brain, all lie at the very extreme of effect sizes in fetal brain, six
are TWAS-significant in fetal brain and all are significant at a
threshold allowing for nine genes (Fig. 2).
Overlap with putative GWAS loci
Thirty-five of the 62 TWAS significant loci, incorporating 56
TWAS-significant genes, could be mapped to within 500 kb
of genome-wide-significant loci reported in the schizophrenia
GWAS upon which this TWAS was based (2) (Supplementary
Material, Table S5). It was possible to distinguish a single signif-
icant TWAS gene at 32 of these loci, after conditioning on other
TWAS signals at the locus (Supplementary Material, Table S6).
At 28 of these, conditioning on the imputed expression of the
candidate gene nominated by TWAS was sufficient to reduce
sentinel SNP associations to below genome-wide significance
(P≥5×10−8) without unmasking a secondary signal, suggesting
that these candidates potentially fully account for the associa-
tion signals at the locus. Conditional regional association plots
for the 32 loci where a single gene was driving the signal are
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Table 1. Transcriptome-wide association study (TWAS) test statistics for 20 novel significantly associated genes for schizophrenia in the
dorsolateral prefrontal cortex (DLPFC). Top GWAS ID denotes the SNP in the gene with the largest schizophrenia GWAS Z-score, GWAS Z is the
corresponding Z-score for this SNP. Top eQTL ID denotes the SNP with the largest DLPFC expression Z-score, Top eQTL Z is the corresponding Z-
score for this SNP. TWAS Z denotes the gene-level TWAS Z-score, TWAS P denotes the gene-level TWAS P value. Genes which represent signals
attributable to a single gene within a TWAS locus are highlighted in bold. Genes which are conditionally independent at loci with multiple
conditionally independent signals are highlighted with an asterisk
Gene Chromosome Gene Start Gene End Top GWAS ID GWAS Z Top eQTL ID Top eQTL Z TWAS Z TWAS P
PTBP2 1 97187174 97280605 rs11165690 4.92 rs17525106 5.96 4.75 2.01E-06
SATB2 2 200134222 200335989 rs769949 8.12 rs10931872 3.43 −4.51 6.54E-06
CGREF1 2 27322220 27341995 rs4665352 −4.20 rs12474099 −3.20 −4.97 6.64E-07
GABRA2 4 46251580 46392056 rs279841 −4.11 rs9291283 −4.52 4.50 6.78E-06
PCDHAC1∗ 5 140306301 140391929 rs991918 4.89 rs753279 −3.40 4.62 3.85E-06
CUL9 6 43149921 43192325 rs6938026 −4.98 rs6924555 −8.17 4.54 5.50E-06
FAM83H 8 144806102 144815914 rs7465067 4.92 rs13277214 8.39 4.67 2.98E-06
STAR 8 38000217 38008600 rs7845911 −6.17 rs2932005 4.45 −4.64 3.50E-06
PXDNL 8 52232136 52722005 rs12674620 4.95 rs7008730 3.73 4.55 5.28E-06
NEURL∗ 10 105253734 105352309 rs12413046 −8.51 rs729211 −3.55 −5.68 1.31E-08
ATP2A2 12 110719031 110788897 rs4766428 7.61 rs28569834 3.67 −4.73 2.25E-06
STAT6 12 57489186 57522883 rs324015 −6.41 rs12307379 6.29 5.05 4.34E-07
RASA3 13 114747193 114898095 rs3812831 −5.14 rs1320468 −4.53 4.44 8.89E-06
ZSCAN29 15 43650369 43662258 rs1079309 −5.03 rs690276 11.50 −4.85 1.22E-06
CPEB1 15 83211950 83316728 rs783540 6.14 rs6603030 5.76 −4.53 5.81E-06
CYB5D2 17 4046461 4060995 rs3760471 4.78 rs8067594 4.25 4.69 2.70E-06
TRIM37 17 57059999 57184266 rs4968363 −4.57 rs2877926 −4.95 5.51 3.67E-08
SLC25A17 22 41165638 41215392 rs926914 6.17 rs80533 −3.95 −4.87 1.09E-06
CRELD2∗ 22 50312282 50321186 rs5770755 4.98 rs910799 3.85 4.49 7.19E-06
MAPK11∗ 22 50702141 50708779 rs5770755 4.98 rs2076139 −4.08 −5.19 2.06E-07
Figure 1. Mirrored Manhattan plot of transcriptome-wide association results. Each point represents a gene, with physical genomic position (chromosome, base-pair)
plotted on the x-axis and association Z-score between gene expression in the dorsolateral prefrontal cortex and schizophrenia plotted on the y-axis. Transcriptome-
wide-significant associations are labeled and highlighted as green (established) or red (novel) points.
shown in Supplementary Material, Figs S2–S33. Twenty-seven
TWAS-significant loci, comprising 33 significant TWAS genes,
fell outside established (genome-wide-significant) schizophre-
nia risk loci (+/−500 kb) as defined by Pardiñas et al. (2). Of these,
24 loci had a signal attributable to one gene (Supplementary
Material, Table S6). TWAS-significant associations at loci not
(yet) implicated in GWAS can arise whenmultiple variants influ-
ence the phenotype through changes in expression, or through
the reduced multiple testing burden of gene-based analysis
(10,14).
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Table 2. Gene-set analysis test statistics for gene sets which survived multiple testing correction. Beta (SE) denotes the regression coefficient
and its corresponding standard error. N cis-h2 genes in set denotes the number of cis-heritable genes in the gene-set used in analysis; N genes
in set denotes the total number of genes in gene-set; P value denotes the association P value; PFDR denotes the P value corrected using a false
discovery rate of 0.05
Gene set Beta (SE) N cis-h2
genes in set
N genes
in set
P value PFDR
Antigen processing and presentation of
peptide antigen via MHC class I (GO:0002474)
1.03 (0.24) 25 98 1.07×10−5 0.023
Abnormal CNS synaptic transmission 0.58 (0.14) 84 392 1.90×10−5 0.023
Figure 2. Correlation between transcriptome-wide association study Z-scores
using expression weights derived from 120 fetal brain homogenate samples
and 452 adult dorsolateral prefrontal cortex samples from the CommonMind
Consortium (CMC). Points represent genes, with genes significant in both adult
and fetal brain tissue highlighted in red, genes significance in adult tissue only
highlighted in purple.
Gene-set analysis
Of the 2390 gene-sets which included at least 10 cis-heritable
genes, significant enrichment after correction for multiple
testing (PFDR ≤0.05) was observed for two gene sets: abnormal
CNS synaptic transmission (16) (PFDR = 0.02) and antigen processing
and presentation of peptide antigen via MHC class I (GO:0002474;
PFDR = 0.02) (Table 2, and Supplementary Material, Table S7 for
all gene sets). Abnormal CNS synaptic transmission contained
six TWAS-significant genes (Supplementary Material, Table
S8, and discussed in the following), but GO:0002474 did not
contain any TWAS-significant genes (Supplementary Material,
Table S9).
To illustrate that gene-set enrichment tests based on well-
powered GWAS and brain-expressed genes do not generate sig-
nificant associations to plausible CNS-related gene sets simply
by virtue of tissue of eQTL origin,weused the sameprocedures to
perform an identical gene-set analysis using summary statistics
from a well-powered GWAS of a non-CNS, but highly heritable
and polygenic, phenotype, namely height (17). Despite yielding
many more (n=287) TWAS-significant genes, no gene sets were
significant using our procedures (minimum PFDR = 0.83).
None of the gene sets which were significant in the MAGMA
(18) analysis of the contributing GWAS (2) were associated
(after correction) in the current analysis, with only abnormal
long term potentiation (MP:0002207) and genes classed as Loss of
Function Intolerant showing nominal significance (P=2.38×10−4
and 0.014, respectively) (Supplementary Material, Table S7). In
particular, the gene-set FMRP targets were not even nominally
significant despite strong evidence for association in that study
(2). One difference between TWAS- and GWAS-MAGMA analyses
is that the former includes only those genes detected to be
significantly cis-heritable, while the latter includes all genes
with SNPs mapping to physical boundaries surrounding the
gene. Thus, TWAS only includes a fraction of the genes that
are included in the GWAS-MAGMA (e.g. here, only 19%). As
the gene-set tests are designed to be competitive (i.e. the
association statistics in the specified set are contrasted against
a background set of all testable genes), this affects both the gene
sets and the background set.
First, we postulated that the cis-heritable subset of FMRP
target genes included in the TWASmight be selectively depleted
of genes that confer the association signal to the gene set
in the GWAS. This hypothesis arose from the observation
that FMRP targets are underrepresented for cis-heritability
relative to other brain-expressed genes, comprising only 3.2% of
genes with cis-heritable expression in DLPFC but 8.9% of genes
expressed in brain-tissue (19) which showed no evidence of
cis-heritability (χ2 test of differences between the proportion
P=3.84× 10−37). However, GWAS-based analysis, implemented
in MAGMA (18), of the genes with (165 genes) and without (652
genes) cis-heritable expression did not support this hypothesis
(cis-heritable sub-set; B=0.31, SE=0.09, PFDR = 2.2×10−4: non-
cis-heritable set; B=0.22, SE=0.05, PFDR = 5.99×10−7), although
the non-cis-heritable set was more significant based on the
greater number of genes included. Second, we tested the effect
of restricting the background of the MAGMA analysis to include
only genes with the DLPFC cis-heritable genes used in the TWAS.
This reduced the significance of GWAS-MAGMA association by
six orders of magnitude (B=0.36, SE=0.10, PFDR = 0.03) relative
to the standard test (B=0.25, SE=0.04, PFDR = 6.01× 10−8). Third,
we determined the overlap of SNP mapping to FMRP targets
in the MAGMA and TWAS analysis. As expected, many fewer
SNPs entered the TWAS than the GWAS-MAGMA analysis
(78 260 vs. 447 742), and of those that did, only 18 112 (i.e.
23% of TWAS SNPs, 4% of MAGMA SNPs) were common to
both analyses. Both the substantial reduction in the number
of SNPs and the poor overlap between MAGMA and TWAS
SNPs credibly explain much of the difference between the two
analyses.
We conclude that the discrepancy between TWAS and GWAS
is not explained by selective depletion of cis-heritable genes for
GWAS association; rather, it is likely a combination of lower
power based on inclusion of fewer genes and SNPs, changes
in the attribution of SNPs to genes and attenuation of signal
based on a more restricted background set. Interestingly, FMRP
targets were significantly associated in the PrediXcan study
(12) study, possibly for related reasons—given this method does
not so markedly constrain the number of genes to those with
demonstrable cis-heritable genes expression.
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Discussion
Summary of findings
In the current study, we identified significant correlations
between cis-expression in the DLPFC and schizophrenia risk at
89 genes, of which 20 are novel.We determined that disease risk
was correlated to the cis-expression of a single gene at 56 loci,
32 of which have previously been implicated by schizophrenia
GWAS. Of these 56 genes, 12 are novel. Prioritizing putative
causal candidate genes and predicted directions of effect at
GWAS loci are important steps towards facilitating functional
experimentation.
To validate our findings, we compared our results to those
obtained using a different methodological approach (SMR) and
with results from a TWAS of independent brain tissue from
fetal samples. Our data showed a strong correlation and, where
our specific novel associated genes were testable, significant
support from both additional analyses. Thus, our results are
reproducible at both themethodological and source tissue levels.
The high correlation between the results of the TWAS based
on fetal and adult gene expression suggests risk alleles for
schizophrenia that influence gene expression often do so in a
relatively (developmentally) non-specific way, but this does not
imply the timing of critical pathogenic events is developmentally
non-specific. Moreover, given the limited sample size of the
samples, this may only apply to cis-acting alleles that have very
large effects on fetal brain (and hence are detectable in the small
fetal brain sample). Better-powered samples that capture more
of the cis-heritable gene expression are needed.
Gene-set analysis of the schizophrenia TWAS results impli-
cated two gene sets after conservative correction. The gene
set GO:0002474 is intriguing given the well-established associ-
ation between schizophrenia and common variation at the MHC
class l, and the long-standing hypotheses relating immunity and
inflammation to the disorder. However, tempting as it is to link
these observations and hypotheses, functional interpretation
of this finding is limited by the absence of any individually
associated genes in the set. Moreover, those genes showing the
strongest evidence of association have a diverse range of pro-
teolytic functions unrelated to antigen processing, for example
PSMA4 encodes a component of the proteasome complex and is
involved in degradation of almost all intracellular proteins. Thus,
we suggest that speculation about the significance of that find-
ing awaits more robust implication of individual genes. In con-
trast, the gene-set abnormal CNS synaptic transmission contains
six TWAS-significant genes and implicates processes relevant
to glutamatergic and GABAergic transmission. These processes
have been implicated by rare variant studies of schizophrenia
(16,20–23), but the findings from common variant studies have,
to date, been equivocal. In the context of being individually
associated, and their membership of biological processes that
are implicated in the disorder, these TWAS-significant genes
represent a particularly interesting subset of candidates for gen-
erating biological hypotheses and are discussed further in the
following.
Candidates within the abnormal CNS synaptic
transmission set
GABRA2, CLCN3, DOC2A, MAPK3, and LRP8 are significantly
upregulated (in cases) while CPEB1 is significantly down-
regulated (Supplementary Material, Table S8). Both GABRA2
and CPEB1 represent novel associations. GABRA2 encodes the
gamma-aminobutyric acid type A (GABAA) receptor alpha-2
subunit which, with other subunits, form GABAA receptors—
the main inhibitory receptors in the CNS. A role for altered
GABAergic function in schizophrenia has been proposed (21–24),
largely on the basis of imaging studies, animal models of
putative intermediate phenotypes and postmortem expression
studies (25). In the latter, consistent with our results, elevated
RNA expression (12) and immunoreactivity (26) for GABRA2
have been observed in the DLPFC from individuals with
schizophrenia.Currently, the postmortem and in vivo imaging data
are not decisive in pointing to a primary excess or decrease of
GABAergic signaling at glutamatergic neurons in schizophrenia
(27). Our finding that elevated cis-expression of GABRA2 is
associated with increased risk of schizophrenia suggests that
the change contributes to pathogenic processes rather than
being simply compensatory (see also CLCN3 in the following) and
suggests the possibility that targeting treatments at antagonism
at this receptor complex might be more appropriate than
agonism, the focus to date. At a wider level, this finding
adds further genetic support for the GABAergic hypothesis of
schizophrenia and complements a recent study which reported
enrichment for components of GABAA receptor complexes in
CNVs in people with schizophrenia (16).
CLCN3 is involved in regulating neurotransmitter vesicle
turnover at both excitatory glutamatergic and inhibitory
GABAergic synapses, can be pre- or postsynaptic and is thought
to be an important regulator of synaptic plasticity (28,29).
Neurotransmitter release at inhibitory GABAergic synapses is
reduced in CLCN3-nullmicewhile glutamate release is increased
(28,29); our finding, and that of another study based on the SMR
approach (15), of increased expression of this genemight suggest
the reverse effect (reduced glutamate, increased GABA) in
schizophrenia consistent with the aberrance of both excitatory
and inhibitory signaling in schizophrenia.
DOC2A and MAPK3, encoding double C2 domain alpha and
mitogen-activated protein kinase 3, respectively,map to 16p11.2,
duplication of which is associated with schizophrenia (30). In
the present study, conditional analysis suggests expression of
both genes contributes to the association signal at this locus,
the conditional evidence being much stronger for expression of
DOC2A (conditional on MAPK3, P=3.5×10−7) than MAPK3 (con-
ditional on DOC2A, P=0.014). Reduction in DOC2A expression
results in a reduction in spontaneous glutamate release from
hippocampal neurons in culture and increases glutamatergic
synaptic efficiency and synaptic efficacy (31), suggesting the
possibility that the increased cis-expression predicted by the
TWAS might result in hypofunction at glutamatergic synapses.
In addition to previously discussed findings implicating MAPK3
in schizophrenia (10), we note that MAPK3 RNA expression is
also found to be increased in the postmortem frontal cortex from
peoplewith schizophrenia, in contrastwith controls, in the study
of Gandal and colleagues (12).
CPEB1 (reduced cis-expression) encoding cytoplasmic poly-
adenylation element-binding protein 1, is expressed in dendrites
where it facilitates activity-dependent mRNA translation (32,33)
andmemory consolidation (34). It has been reported to bind, and
act antagonistically to, FMRP which is a translational repressor
(34), targets of which have been repeatedly linked to schizophre-
nia (2,19,35). Moreover, a recent study (36) has shown that CPEB4
protein is an important regulator of a large number of autism-
associated genes. Our study suggests the possibility that CPEB1
might similarly regulate genes that play a role in schizophrenia,
possibly by interaction with FMRP.
LRP8, which encodes LDL receptor-related protein 8, is widely
expressed, but is particularly highly expressed in the develop-
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ing fetal brain (37). LRP8 is a component of the NMDA recep-
tor complex (NMDA-R) (38), which has repeatedly implicated
in schizophrenia (16,35,39). It is also the major receptor, and
effector, of the actions of reelin as a modulator of plasticity,
memory and learning in the adult brain (40). It should be noted
that LRP8 has non-synaptic functions of credible relevance to
schizophrenia, including mediating reelin-related functions on
neuronal migration, neurogenesis and neuronal differentiation
(41). However, these processes are not implicated by the gene-
set analysis.
Comparison with existing TWAS literature
Of the 89 TWAS significant genes, 11 overlapwith genes reported
as significant by Huckins et al. (11), and 45 overlap with those
reported as significant Gandal et al. (12). The novel genes pre-
sented in each study, despite using the same GWAS summary
statistics (2), is to be expected based on the analytical differ-
ences between these studies. Huckins et al. used a cross-brain-
tissue approach implemented in PrediXcan, which has differ-
ent inclusion criteria and a different modeling approach (using
exclusively ‘enet’ regression method, where FUSION employs
four regression frameworks).
Gandal et al., as in the current manuscript, employed a
FUSION-based approach, but utilized brain weights derived
from the PsychENCODE consortium (N=1321), which combine
multiple brain regions from several studies. This increased
statistical power in the expression dataset results in a starting
set of 14 750 significantly cis-h2 genes for analysis.
There are strengths and limitations to the various approaches.
Taking a more inclusive approach to expression source tissue
may well increase power to detect larger numbers of genes,
although based on substantial regional differences in gene
expression, the opposite is sometimes true as shown by Collado-
Torres et al. (42). In contrast, restricting the analysis to a single
tissue considerably simplifies pathway-based competitive tests,
as it minimizes biases towards finding association with genes
expressed in multiple tissues or samples, genes which are
not likely to be random with respect to gene-set membership,
violating the assumptions of the competitive test.
Conclusion
In summary, we have undertaken a single tissue TWAS exploit-
ing the largest available published schizophrenia GWAS dataset.
We identify 20 novel genes whose expression correlates with
schizophrenia, six of which implicate processes of high bio-
logical plausibility related to synaptic function. Our findings
are congruent with those employing different methodologies
and with expression in the fetal brain. These candidate genes,
to which we assign predicted directions of effect, could facili-
tate experimental studies geared towards a better mechanistic
understanding of schizophrenia pathogenesis.
Materials and Methods
Datasets
We performed TWAS using GWAS summary statistics from the
CLOZUK+PGC2 schizophrenia meta-analysis (2) (40 675 cases,
64 643 controls). Summary statistics were filtered prior to use
in FUSION using the munge_sumstats.py (v2.7.13) script, dis-
tributed as part of the LD score regression package (URLs). Given
its localized pattern of long-range and complex LD, variants
within the extendedMHC region (chr6:28477797–33448354)were
excluded, leaving 6 414705 polymorphisms.
Pre-computed expression weights for 5420 genes with cis-
heritable expression in the DLPFC were obtained from the
FUSION website (URLs). Weights were calculated using bulk
RNA sequence and genotype data from schizophrenia cases,
bipolar cases and control subjects as part of the CommonMind
Consortium(15) (N=452). Gene-expression and genotype data
from the CMC were processed prior to weight derivation using
the GTEx Consortium guidelines for eQTL analysis of RNA-Seq
data, described in detail elsewhere (10,15).
Reference haplotypes from the 1000 Genomes European sub-
population were also obtained from the FUSION website.
Transcriptome-wide association study
TWASwas performed in FUSION (9), using the FUSION.assoc.test.R
script with default parameters over all autosomes (URLs).
Multiple-testing correction was applied using the Bonferroni
method. Where multiple proximal (+/− 500 kb) genes reported
a significant TWAS association, statistically independent
signals were discriminated via conditional analysis using the
FUSION.post_process.R script with default parameters. Genes
which remained significant after conditional analysis and
locus-wide Bonferroni correction (conditional P≤0.05/2∗Ngenes,
to account for pairwise testing) were considered statistically
independent.
Correlation with results from summary-based
Mendelian randomization
To assess the robustness of our findings to a different analytical
method and an only partially overlapping expression dataset,we
performed a Pearson’s rank correlation test between the effect
size estimates from our TWAS analysis and those derived from
SMR as implemented in (12), for the subset (N=4327) of genes
present in both datasets.
Correlation with brain-based gene expression in the
fetal brain
To assess the robustness of our results to tissue source, and also
the relevance of our findings with respect to gene regulation
in early development, we repeated the TWAS analysis using
expression weights for 1280 genes with cis-heritable expression
in fetal whole brain tissue. Weights were derived, using the
FUSION pipeline, from whole transcriptome RNA sequencing
of brain homogenate samples and genome-wide genotyping of
120 human fetuses aged 12–19 post-conception weeks, the pro-
cessing of which is described in detail elsewhere (43). Multiple-
testing correction was applied using the Bonferroni method.
TWAS Z-scores from genes analyzed in both adult and fetal brain
tissue (N=386) were subjected to a Pearson’s rank correlation
test.
Overlap with putative GWAS loci
Significant TWAS loci were mapped to the genomic coordinates
for 145 schizophrenia-associated loci from the meta-analysis
(2). At each locus containing a TWAS signal which could
be attributed to a single gene, locus-wide GWAS statistics
were conditioned on imputed gene expression using the
FUSION.post_process.R script. The change in P value of the most
significant polymorphism within the locus, before and after
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conditional analysis, was used to evaluate the effect of imputed
expression on phenotypic (schizophrenia) association.
Gene-set enrichment analysis
A competitive gene-set enrichment analysis was performed
using a parallel approach to MAGMA (44, URLs), implementing a
mixed linear regression framework, fitted using the lme4qtl
package (45), in R (46). The model fitted probit-transformed
TWAS Z-score as the dependent variable and gene-set member-
ship as a linear predictor, covarying for gene-length and number of
SNPs in the gene as fixed effects, and a correlation matrix of gene
expression as a random effect to account for non-independent
association arising both from linkage disequilibrium and close
physical distance between genes. The correlation matrix was
computed by imputing predicted gene expression values,
using the same CommonMind Consortium expression weights
for genes (N=5301) as the primary analysis, into the 1000
Genomes European subpopulation (N=489). The correlation
between genes that were more than 5 Mb apart, on separate
chromosomes or had a linkage disequilibrium R2 < 0.0001 were
set to zero. This was carried out for 2390 gene sets which
contained 10 or more cis-heritable genes, representing a TWAS-
informative subset of a larger data-driven, comprehensive
annotation of gene sets from multiple databases (N=6677), as
per Pardiñas et al. (2). In brief, this analysis comprised custom
annotated CNS gene sets (16); a gene set of genes intolerant to
loss-of-function mutations (20); gene sets from Gene Ontology
database release 01/02/2016 (47,48); the fourth ontology level of
the MGI database version 6(49); REACTOME version 55 (50); KEGG
release 04/2015 (51); and OMIM release 01/02/2016 (52). Further
details about these gene sets can be found here (2,16). Gene
sets were corrected for multiple testing using a 5% Benjamini &
Hochberg false discovery rate (FDR).
URLs
Schizophrenia GWAS summary statistics:
https://walters. psycm.cf.ac.uk/.
FUSION scripts, SNP-weights for CMC and 1000 genomes
reference panel plink files: http://gusevlab.org/projects/fusion/
TWAS-based gene-set enrichment analysis software:
https://github.com/opain/TWAS-GSEA
LD Score Regression:
https://github.com/bulik/ldsc
BRAINSPAN transcriptomes:
http://www.brainspan.org/static/download.html
Supplementary Material
Supplementary material is available at HMG online.
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